Our expertise includes therapeutics, vaccines, medical devices, clinical diagnostics and emerging cell and gene therapy applications.
Human Health: Strategy and Operations support for Dolon Limited
Ronnie has in depth understanding of the IP and product development lifecycle of human health technologies coupled with practical business development and licensing experience. Ronnie joined IP Pragmatics in 2007, following an early career in managing late-stage small molecule and biological therapeutics in big pharma in Australia and the UK,. He supports universities, research agencies and private and publicly-listed SMEs in the UK, Australia, New Zealand and overseas to assess and validate their commercialisation opportunities, secure funding and realise licensing/partnering opportunities.
In depth sector knowledge
Our human health team have career backgrounds that include in- and out-licensing, business development, research and academic liaison positions within multinational companies such as AstraZeneca, GSK, Roche, Charles River and Eli Lilly, as well as individuals who have worked within university technology transfer offices, healthcare-focussed venture capital and a university seed fund.
Broad technology and development stage experience
We work with technology opportunities across the clinical development pathway from discovery through to late-stage clinical candidates. Clients leverage our extensive market intelligence built from previous projects, our subscription databases, attendance at global industry events and through our personal industry networks.
We maintain extensive contacts globally across the pharma and biotech sector. We have experienced staff with pharma backgrounds based in London, Edinburgh, New York and Sydney with access to local markets for market intelligence and partnering.
Human Health: Valuation of a royalty stream due to The Institute of Cancer Research
Human Health: Market assessment of Otago Innovation diagnostic technology
- Leading contract negotiations on behalf of big pharma clients under the Innovative Medicine’s Initiative for 20 IMI projects valued at €5-10 million each.
- Multiyear contract to advise on operations and the strategic growth of a market access company focussed on rare and severe disease medicines for mid- and large-pharma clients, that has almost doubled in size in this period.
- Supporting the development of a business plan and start-up of a pharma SME as part of a significant fund raising round and appointed to advise on a subsequent Ph2a Proof-of-Concept clinical trial after the successful funding round.
- Undertaking valuations for a meningitis B vaccine clinical phase candidate and a respiratory syncytial virus pre-clinical vaccine candidate for a Dutch government institute, including providing business development support to help the client complete a major joint development and licensing agreement.
Our clients include universities, research institutes, SMEs, large enterprise and public sector organisations in over 20 countries.
We recognise and understand what is important to our clients and their stakeholders. This enables us to provide meaningful outcomes and practical next steps for all client assignment.